BIOMAT Database Logo BIOMAT Database Logo

Effect of intranasal glucagon on blood glucose levels in healthy subjects and hypoglycaemic patients with insulin-dependent diabetes. 1988

L Freychet, and S W Rizkalla, and N Desplanque, and A Basdevant, and P Zirinis, and G Tchobroutsky, and G Slama
Department of Diabetes, Hôtel-Dieu Hospital, Paris, France.

Glucagon in solution with a surfactant (deoxycholic acid 1% w/v) was administered by intranasal spray to 6 healthy fasting subjects and 6 insulin-dependent diabetics with insulin-induced hypoglycaemia. In the normal subjects, intranasal glucagon increased plasma glucose levels, with a dose-response effect. In the diabetic patients, plasma glucose levels showed a mean increase of 100% above nadir values in approximately 26 min in response to 7.5 mg intranasal glucagon; hypoglycaemic symptoms were relieved within about 7 min. These results suggest that intranasal glucagon is effective and may represent an alternative to parenteral glucagon or glucose or to oral sugar as the first-line treatment of hypoglycaemic episodes in insulin-dependent diabetics.

UI MeSH Term Description Entries
D007003 Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH. Fasting Hypoglycemia,Postabsorptive Hypoglycemia,Postprandial Hypoglycemia,Reactive Hypoglycemia,Hypoglycemia, Fasting,Hypoglycemia, Postabsorptive,Hypoglycemia, Postprandial,Hypoglycemia, Reactive
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D005260 Female Females
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L Freychet, and S W Rizkalla, and N Desplanque, and A Basdevant, and P Zirinis, and G Tchobroutsky, and G Slama
Effect of a 12-hour subcutaneous infusion of somatostatin-14 on blood glucose, insulin and glucagon levels in healthy subjects and insulin dependent diabetics.
January 1986, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
L Freychet, and S W Rizkalla, and N Desplanque, and A Basdevant, and P Zirinis, and G Tchobroutsky, and G Slama
Cutaneous blood flow during a hypoglycaemic clamp in insulin-dependent diabetic patients and healthy subjects.
June 1992, Clinical science (London, England : 1979),
L Freychet, and S W Rizkalla, and N Desplanque, and A Basdevant, and P Zirinis, and G Tchobroutsky, and G Slama
Bioavailability of glipizide and its effect on blood glucose and insulin levels in patients with non-insulin-dependent diabetes.
January 1982, Diabetes care,
L Freychet, and S W Rizkalla, and N Desplanque, and A Basdevant, and P Zirinis, and G Tchobroutsky, and G Slama
Intranasal glucagon raises blood glucose concentrations in healthy volunteers.
August 1983, British medical journal (Clinical research ed.),
L Freychet, and S W Rizkalla, and N Desplanque, and A Basdevant, and P Zirinis, and G Tchobroutsky, and G Slama
The effect of various blood glucose levels on post-glucagon C-peptide secretion in type 2 (non insulin-dependent) diabetes.
February 1992, Journal of endocrinological investigation,
L Freychet, and S W Rizkalla, and N Desplanque, and A Basdevant, and P Zirinis, and G Tchobroutsky, and G Slama
Regulation of hepatic glucose production in healthy subjects and patients with non-insulin-dependent diabetes mellitus.
October 1995, Diabete & metabolisme,
L Freychet, and S W Rizkalla, and N Desplanque, and A Basdevant, and P Zirinis, and G Tchobroutsky, and G Slama
Calcium-antagonistic effects on glucose response to glucagon in patients with non insulin-dependent diabetes mellitus and in normoglycemic subjects.
December 1981, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
L Freychet, and S W Rizkalla, and N Desplanque, and A Basdevant, and P Zirinis, and G Tchobroutsky, and G Slama
Effect of chloroquine on insulin and glucose homeostasis in normal subjects and patients with non-insulin dependent diabetes mellitus.
April 1987, British medical journal (Clinical research ed.),
L Freychet, and S W Rizkalla, and N Desplanque, and A Basdevant, and P Zirinis, and G Tchobroutsky, and G Slama
Effect of chloroquine on insulin and glucose homoeostasis in normal subjects and patients with non-insulin-dependent diabetes mellitus.
February 1987, British medical journal (Clinical research ed.),
L Freychet, and S W Rizkalla, and N Desplanque, and A Basdevant, and P Zirinis, and G Tchobroutsky, and G Slama
Alcohol causes hypoglycaemic unawareness in healthy volunteers and patients with type 1 (insulin-dependent) diabetes.
April 1990, Diabetologia,
Copied contents to your clipboard!